Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL) Short Interest Update

Key Points

• Adlai Nortye Ltd. experienced a significant 61.8% decrease in short interest in September, with totals dropping from 3,400 shares to 1,300 shares as of September 15th.
• The company's stock currently trades at $1.77, with a 52-week low of $1.10 and a high of $3.89.
• Adlai Nortye is a clinical-stage biotechnology firm focusing on cancer therapies, with its lead product, AN2025, undergoing Phase III clinical trials.

Adlai Nortye Ltd. Sponsored ADR (NASDAQ:ANL - ) saw a significant decrease in short interest in September. As of September 15th, there was short interest totaling 1,300 shares, a decrease of 61.8% from the August 31st total of 3,400 shares. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is currently 0.2 days. Based on an average daily trading volume, of 8,500 shares, the days-to-cover ratio is currently 0.2 days.

Adlai Nortye Price Performance

ANL stock traded down $0.03 during mid-day trading on Thursday, reaching $1.77. 20,254 shares of the stock traded hands, compared to its average volume of 12,731. The stock's fifty day moving average is $1.67 and its 200-day moving average is $1.76. Adlai Nortye has a 52-week low of $1.10 and a 52-week high of $3.89.

About Adlai Nortye

Adlai Nortye Ltd., a clinical-stage biotechnology company, focuses on the discovery and development of cancer therapies in the United States and Mainland China. Its lead product is AN2025, a pan-phosphoinositide 3-kinase inhibitor, which is in Phase III clinical trial for the treatment of recurrent or metastatic head and neck squamous cell carcinomas.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.